FDA Approves Lilly’s New Oral Combo Pill for Common Breast Cancer Mutation
The Eli Lilly corporate headquarters in Indianapolis, IN, on August 15, 2024. AJ Mast/Bloomberg via Getty Images The FDA approved a new oral combo drug for a common breast cancer mutation on September 18. The treatment includes Inluriyo (imlunestrant) taken with Verzenio (abemaciclib) for adults with ER-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutation that has…
We haven't written up this one. Healthline News has the full story — the link below goes straight to it.
